Literature DB >> 12833141

PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner.

Lluis Fajas1, Viviane Egler, Raphael Reiter, Stéphanie Miard, Anne-Marie Lefebvre, Johan Auwerx.   

Abstract

The nuclear receptor PPARgamma is implicated in the control of cell proliferation and apoptosis. However, the molecular mechanisms by which it controls these processes remain largely elusive. We show here that PPARgamma activation in the presence of the retinoblastoma protein (RB) results in the arrest of cells at the G1 phase of the cell cycle, whereas in the absence of RB, cells accumulate in G2/M, endoreduplicate, and undergo apoptosis. Through the use of HDAC inhibitors and coimmunoprecipitations, we furthermore demonstrate that the effects of RB on PPARgamma-mediated control of the cell cycle and apoptosis depend on the recruitment of histone deacetylase 3 (HDAC3) to PPARgamma. In combination, these data hence demonstrate that the effects of PPARgamma on cell proliferation and apoptosis are dependent on the presence of an RB-HDAC3 complex.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833141     DOI: 10.1038/sj.onc.1206530

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.

Authors:  Vanessa Fritz; Zohra Benfodda; Geneviève Rodier; Corinne Henriquet; François Iborra; Christophe Avancès; Yves Allory; Alexandre de la Taille; Stéphane Culine; Hubert Blancou; Jean Paul Cristol; Françoise Michel; Claude Sardet; Lluis Fajas
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

2.  Discovery of Transcriptional Targets Regulated by Nuclear Receptors Using a Probabilistic Graphical Model.

Authors:  Mikyung Lee; Ruili Huang; Weida Tong
Journal:  Toxicol Sci       Date:  2015-12-07       Impact factor: 4.849

3.  ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.

Authors:  V Duong; A Licznar; R Margueron; N Boulle; M Busson; M Lacroix; B S Katzenellenbogen; V Cavaillès; G Lazennec
Journal:  Oncogene       Date:  2006-03-16       Impact factor: 9.867

4.  Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells.

Authors:  Glen W Humphrey; Yong-Hong Wang; Tazuko Hirai; Raji Padmanabhan; David M Panchision; Laura F Newell; Ronald D G McKay; Bruce H Howard
Journal:  Differentiation       Date:  2007-11-15       Impact factor: 3.880

5.  The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.

Authors:  Zhenzhen Tu; Hui Li; Yuxiang Ma; Bin Tang; Junmei Tian; Walter Akers; Samuel Achilefu; Yueqing Gu
Journal:  Mol Cell Biochem       Date:  2012-04-04       Impact factor: 3.396

6.  Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock.

Authors:  Ranjit S Chima; Paul W Hake; Giovanna Piraino; Prajakta Mangeshkar; Michael O'Connor; Basilia Zingarelli
Journal:  Int J Clin Exp Med       Date:  2010-01-01

7.  Peroxisome proliferator activated receptor-γ and the ubiquitin-proteasome system in colorectal cancer.

Authors:  Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2010-05-15

Review 8.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27

9.  Psammaplin A inhibits hepatitis C virus NS3 helicase.

Authors:  Kazi Abdus Salam; Atsushi Furuta; Naohiro Noda; Satoshi Tsuneda; Yuji Sekiguchi; Atsuya Yamashita; Kohji Moriishi; Masamichi Nakakoshi; Masayoshi Tsubuki; Hidenori Tani; Junichi Tanaka; Nobuyoshi Akimitsu
Journal:  J Nat Med       Date:  2013-01-29       Impact factor: 2.343

10.  Current understanding of the role of PPARγ in gastrointestinal cancers.

Authors:  Bing Zou; Liang Qiao; Benjamin C Y Wong
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.